A first‑in‑human CRISPR gene‑editing therapy produced dramatic reductions in LDL cholesterol and triglycerides in an early study of 15 patients, according to STAT reporting from the AHA meeting and the New England Journal of Medicine. The single‑course editing targets lipid metabolism genes to durably lower atherosclerotic risk factors. Investigators flagged safety questions, notably potential liver toxicities, and stressed that the data are preliminary. The study illustrates both the therapeutic promise of permanent editing for common cardiometabolic disease and the tradeoffs clinicians and regulators will weigh on durability versus safety.